Novartis: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Novartis (NYSE:NVS) raised its full-year 2026 core operating income guidance after delivering 4% net sales growth. This performance matters for long-term investors because the pharmaceutical giant is demonstrating that expanding sales from recently launched drugs can successfully replace revenue from older medicines losing patent protection. Three key insights from management explain how the company is maintaining its growth trajectory.

1. Higher Profit Guidance Signals Resilience Against Generic Erosion

Novartis raised its full-year 2026 core operating income guidance, which tracks non-GAAP (adjusted) operating profit before one-time items, to in-line to low-single-digit growth, up from a previously projected decline. This operational shift shows that rising sales of priority medicines are offsetting patent expirations for key legacy treatments.

We now expect for the full year 2026, core operating income to be in line to growing low single digit. For reference, this is an upgrade from the previous guidance of core operating income of low single digit decline for the full year.
-- Mukul Mehta, Chief Financial Officer

2. Multibillion-Dollar Pipeline Upgrades Expand Long-Term Growth Potential

Management upgraded peak sales projections for key pipeline drugs, including Rhapsido for skin conditions such as chronic spontaneous urticaria (CSU), where hives appear without clear triggers. Promising trial results for remibrutinib in relapsing multiple sclerosis (RMS), a central nervous system disorder, further reinforce the company's ability to replace aging therapies.

So we are upgrading our peak sales guidance for Rhapsido in CSU and CIndU combined to over $4 billion.
-- Robert Kowalski, President of Development

3. Overhead Expense Reductions Pave the Way to Expanded Operating Margins

Selling, general, and administrative (SG&A) expenses, which cover marketing and operational overhead, fell 7% during the third quarter. Lower third-party spending and efficiency gains from technology are driving progress toward a target of 40% core operating margin by 2029.

If you look at SG&A for the quarter, we have actually seen SG&A 7% lower in Q3 versus previous year, while the company from a top line perspective has shown a growth of 4%.
-- Mukul Mehta, Chief Financial Officer

Looking Ahead

Sales momentum across newly launched drugs is outpacing legacy revenue losses, and management is openly highlighting this replacement capability. The company benefits from commercial scale across international markets and a deep pipeline, while management tracks patent litigation outcomes and pricing discipline.

We delivered strong growth in the quarter driven by our priority brands and launches.
-- Vasant Narasimhan, Chief Executive Officer

Capital allocation remains focused on steady dividend growth and targeted share repurchases, supported by free cash flow generation. The long-term thesis hinges on whether late-stage clinical readouts maintain this momentum over the coming years.

We grow the dividend in Swiss francs every year as we have now done for almost 30 years. We are committed to investing in the core business.
-- Vasant Narasimhan, Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.